Broker upgrade, page-21

Would be nice to get some further data, but I can't see that the annual report - which refers to activities in the last year - will contain this. The next announcements should be about STORM and CANON trials, over the next few months. However anything could come out of left field and I was interested to read factor's post above which gives a new potential.

Montrachet, licensing CAVATAK for $200m seems a poor return on its potential. I'd hope for a lot more!